Skip to main content

Carisma Therapeutics Inc.

CARMDelisted Dec 15, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001485003

Carisma Therapeutics Inc. was delisted on Dec 15, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 33 institutions reported holding it in 13F filings for Q3 2025, worth $842.6K in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Carisma Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Carisma Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Carisma Therapeutics Inc.
NameTitleLast reported holdingLast filingFilings, past year
Klichinsky MichaelChief Scientific Officer0Oct 8, 20252
Kelly StevenPresident and CEO–Jan 30, 20250
Cheng Sohanya RoshanDirector–Nov 1, 20240
Scadden DavidDirector–Jul 1, 20240
Thorell MarellaDirector–Jul 1, 20240
Zweifach Sanford SDirector413Jun 27, 20240
Morrison BriggsDirector12,175Jun 27, 20240
Hohneker JohnDirector–Jun 27, 20240
Torok MichaelDirector50,000IndirectJun 27, 20240
Morris Richard StevenChief Financial Officer–Jun 18, 20240
Ugwumba ChidozieDirector2,215,877IndirectJun 8, 20230
Hodits ReginaDirector2,297,546IndirectMar 9, 20230
Sullivan MarkGeneral Counsel & Secretary378,651Mar 6, 20230
Cannell Thomas RPresident and CEO672,386Mar 6, 20230
Forbes MonicaChief Financial Officer505,664Mar 6, 20230
MacDonald Glen CChief Technology Officer398,918Mar 6, 20230
Ryu EllyPrincipal Accounting Officer148,624Mar 6, 20230
Honig PeterDirector40,000Jun 24, 20220
Duker Jay S.Director40,000Jun 24, 20220
Bourdow Carrie L.Director40,000Jun 24, 20220
Keyes Jason ADirector40,000Jun 24, 20220
Jewett Michael A. S.Director40,000Jun 24, 20220
Rosales MinoriChief Development Officer–Jan 26, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 8, 2025 (view filing)4:16 PM ETOct 71 dayKlichinsky MichaelChief Scientific OfficerSSale−57.0K$0.2542−$14.5K−100.0%0 after
Oct 3, 2025 (view filing)5:25 PM ETOct 1-32 daysKlichinsky MichaelChief Scientific OfficerSSale−484.3K$0.2567−$124.3K−100.0%0 after3 lots
Mar 6, 2023 (view filing)Mar 24 daysSullivan MarkGeneral Counsel & SecretarySSale−219.2K$0.59−$129.3K−36.7%378.7K after3 lots
Mar 6, 2023 (view filing)Mar 24 daysMacDonald Glen CChief Technology OfficerSSale−170.4K$0.59−$100.5K−29.9%398.9K after3 lots
Mar 6, 2023 (view filing)Mar 24 daysRyu EllyPrincipal Accounting OfficerSSale−17.3K$0.59−$10.2K−10.4%148.6K after
Mar 6, 2023 (view filing)Mar 24 daysCannell Thomas RPresident and CEOSSale−487.5K$0.59−$287.6K−42.0%672.4K after2 lots
Mar 6, 2023 (view filing)Mar 24 daysForbes MonicaChief Financial OfficerSSale−345.8K$0.59−$204.1K−40.6%505.7K after3 lots
Feb 23, 2023 (view filing)Feb 212 daysSullivan MarkGeneral Counsel & SecretarySSale−39.8K$0.59−$23.5K−11.7%299.7K after
Feb 23, 2023 (view filing)Feb 212 daysRyu EllyPrincipal Accounting OfficerSSale−7.16K$0.59−$4.22K−4.1%165.9K after
Feb 23, 2023 (view filing)Feb 212 daysCannell Thomas RPresident and CEOSSale−53.7K$0.59−$31.7K−8.9%553.1K after
Feb 23, 2023 (view filing)Feb 212 daysForbes MonicaChief Financial OfficerSSale−61.9K$0.59−$36.5K−11.4%480.4K after
Feb 23, 2023 (view filing)Feb 212 daysMacDonald Glen CChief Technology OfficerSSale−25.9K$0.59−$15.3K−8.4%283.0K after